Search results
Results From The WOW.Com Content Network
Liver failure; Pancreatitis (these two usually occur in first 6 months and can be fatal); Leukopenia (low white blood cell count); Neutropenia (low neutrophil count); Pure red cell aplasia
Routes can also be classified based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but is delivered by routes other than the GI tract). Route of administration and dosage form are aspects of drug delivery.
Transient and/or dose-related hair loss; Dysmenorrhea; Haemorrhage (bleeding) Weight gain [c] Uncommon (0.01-0.1% frequency) ... List of adverse effects of valproate ...
The term dosage form may also sometimes refer only to the pharmaceutical formulation of a drug product's constituent substances, without considering its final configuration as a consumable product (e.g., capsule, patch, etc.). Due to the somewhat ambiguous nature and overlap of these terms within the pharmaceutical industry, caution is ...
This page was last edited on 17 June 2015, at 07:32 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may ...
Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein.The intravenous route of administration is commonly used for rehydration or to provide nutrients for those who cannot, or will not—due to reduced mental states or otherwise—consume food or water by mouth.
Intraosseous access has roughly the same absorption rate as IV access, and allows for fluid resuscitation. For example, sodium bicarbonate can be administered IO during a cardiac arrest when IV access is unavailable. [1] High flow rates are attainable with an IO infusion, up to 125 milliliters per minute.
This is the list of Schedule IV controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule III.